Last reviewed · How we verify
NCT04381351: MiRCOVID
Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction
trial in COVID-19 in 50 participants. Status unknown.
1 March 2021
Quick facts
| Lead sponsor | Heinrich-Heine University, Duesseldorf |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 16 April 2020 |
| Primary completion | 1 March 2021 |
| Estimated completion | 31 July 2021 |
| Sites | 1 location across Germany |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Heinrich-Heine University, Duesseldorf
Who can join
Adults 18 to 90, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, critically ill patients with highly suspected or confirmed COVID-19 will be included. Main goal is the identification of noncoding RNAs in COVID-19 associated organ dysfunction with an emphasis on acute kidney injury.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prediction of COVID-19 severity using machine learning.
Karaduzovic-Hadziabdic K, Adilovic M, Zhang L, Lumley AI, et al · · 2024 · cited 1× · PMID 39370709 · DOI 10.1002/ctm2.70042
Verify or expand the search:
- PubMed search for NCT04381351
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Heinrich-Heine University, Duesseldorf trials
Trials by the same sponsor.
- NCT04993508 — Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Co · NA · not yet recruiting
- NCT07385482 — Chronic and Acute Cardiovascular Diseases in Elderly Intensive Care Patients · not yet recruiting
- NCT07455097 — COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) · active not recruiting
- NCT07254663 — GEL & MEDication Dysphagia · recruiting
- NCT06313944 — German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04381351 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heinrich-Heine University, Duesseldorf
- Last refreshed: 27 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04381351.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing